Spots Global Cancer Trial Database for tumor microenvironment
Every month we try and update this database with for tumor microenvironment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | NCT06182657 | Nasopharyngeal ... Pathologic Comp... Tumor Microenvi... | 18 Years - | Jiangxi Provincial Cancer Hospital | ||
| FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues | NCT05698082 | Colorectal Canc... Monkey Pox | Immunohistochem... | 18 Years - 75 Years | Cancer Hospital of Guangxi Medical University | |
| Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells | NCT01286883 | Colorectal Canc... | 18 Years - | Milton S. Hershey Medical Center | ||
| Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy | NCT06202781 | Gastric Cancer Tumor Microenvi... Immunotherapy Chemotherapy | SOX plus PD-1 i... Gastroscopic bi... | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | NCT02042781 | Advanced Solid ... | PG545 | 18 Years - | Zucero Pty Ltd | |
| Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy | NCT06331585 | Low-dose Radiot... Tumor Microenvi... Non-Small Cell ... | low dose radiot... | 18 Years - 80 Years | Hetian District People's Hospital | |
| Gut Microbiota in People With Hepatocellular Carcinoma (HCC) | NCT02599909 | Hepatocellular ... Liver Cancer Liver Cell Cari... Liver Neoplasm | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01) | NCT04003558 | Breast Neoplasm... Early-stage Bre... Radiomics Axillary Lymph ... Survival, Prost... | No intervention... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | NCT04850729 | Gastric Adenoca... Gastroesophagea... | non-interventio... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| PSMA-specific CAR-T Cell Therapy | NCT04429451 | PSMA Positive T... | 4SCAR-PSMA T ce... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | NCT04850729 | Gastric Adenoca... Gastroesophagea... | non-interventio... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Naltrexone and Propranolol Combined With Immunotherapy | NCT05968690 | Advanced Melano... | Propranolol Naltrexone | 18 Years - | Rutgers, The State University of New Jersey | |
| Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma | NCT05941234 | Glioblastoma, I... | Biological biom... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | NCT06366451 | Head and Neck S... | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | NCT06436040 | Tumor Microenvi... Lung Squamous C... Neoadjuvant Che... | Pathological re... | 40 Years - 80 Years | Tang-Du Hospital | |
| Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer | NCT03168139 | Metastatic Colo... Metastatic Panc... | Olaptesed pegol... Olaptesed pegol... | 18 Years - | TME Pharma AG | |
| Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | NCT02042781 | Advanced Solid ... | PG545 | 18 Years - | Zucero Pty Ltd | |
| Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | NCT04121455 | Glioblastoma | Olaptesed pegol Radiotherapy Bevacizumab Pembrolizumab | 18 Years - | TME Pharma AG | |
| Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | NCT06436040 | Tumor Microenvi... Lung Squamous C... Neoadjuvant Che... | Pathological re... | 40 Years - 80 Years | Tang-Du Hospital | |
| Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | NCT04065555 | Head and Neck C... | TAK-981 Cetuximab Avelumab TAK-981 + Cetux... TAK-981 + Avelu... | 18 Years - | Presage Biosciences | |
| Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01) | NCT04003558 | Breast Neoplasm... Early-stage Bre... Radiomics Axillary Lymph ... Survival, Prost... | No intervention... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Transcriptomic Signatures in Gastric Adenocarcinoma | NCT05319392 | Gastric Adenoca... | Observational s... | 18 Years - 80 Years | Sanjay Gandhi Postgraduate Institute of Medical Sciences | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | NCT03727880 | Resectable Panc... Pancreatic Duct... | Pembrolizumab Defactinib | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | NCT04121455 | Glioblastoma | Olaptesed pegol Radiotherapy Bevacizumab Pembrolizumab | 18 Years - | TME Pharma AG | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Prehabilitation Exercise Program in Breast Cancer: Effects on Quality of Life and Tumor Microenvironment (PEP_BC) | NCT06360809 | Breast Cancer | Prehabilitation... | 18 Years - 65 Years | Institut Nacional d'Educacio Fisica de Catalunya | |
| Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells | NCT01286883 | Colorectal Canc... | 18 Years - | Milton S. Hershey Medical Center | ||
| Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment | NCT06230965 | Tumor Microenvi... | Lung protective... | 51 Years - 70 Years | Affiliated Hospital of Nantong University | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer | NCT03168139 | Metastatic Colo... Metastatic Panc... | Olaptesed pegol... Olaptesed pegol... | 18 Years - | TME Pharma AG | |
| OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer | NCT03661047 | Colon Cancer | AMR101 (VASCEPA... | 18 Years - | Massachusetts General Hospital | |
| Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | NCT06436040 | Tumor Microenvi... Lung Squamous C... Neoadjuvant Che... | Pathological re... | 40 Years - 80 Years | Tang-Du Hospital | |
| Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment | NCT06387134 | Early Stage Lun... | Lifei Xiaoji Wa... Conventional tr... | 18 Years - 75 Years | Henan University of Traditional Chinese Medicine | |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | NCT04850729 | Gastric Adenoca... Gastroesophagea... | non-interventio... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer | NCT02977468 | Triple Negative... | Merck 3475 Pemb... Intraoperative ... | 21 Years - 80 Years | Columbia University | |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | NCT03727880 | Resectable Panc... Pancreatic Duct... | Pembrolizumab Defactinib | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Transcriptomic Signatures in Gastric Adenocarcinoma | NCT05319392 | Gastric Adenoca... | Observational s... | 18 Years - 80 Years | Sanjay Gandhi Postgraduate Institute of Medical Sciences | |
| Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | NCT03512340 | Advanced Solid ... Hematologic Can... | SRF231 | 18 Years - 99 Years | Surface Oncology | |
| The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | NCT06182657 | Nasopharyngeal ... Pathologic Comp... Tumor Microenvi... | 18 Years - | Jiangxi Provincial Cancer Hospital | ||
| Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | NCT03768531 | Resectable Bili... | Nivolumab Cabrilizumab | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC | NCT06062602 | Head and Neck S... | TAK-676 Carboplatin 5-FU Paclitaxel TAK-676 + Carbo... Carboplatin + P... Carboplatin + 5... TAK-676 + Carbo... TAK-676 + Carbo... | 18 Years - | Presage Biosciences | |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma | NCT03056599 | Soft Tissue Sar... | Multiple drug m... CIVO device | 18 Years - | Presage Biosciences | |
| Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma | NCT05941234 | Glioblastoma, I... | Biological biom... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | NCT04065555 | Head and Neck C... | TAK-981 Cetuximab Avelumab TAK-981 + Cetux... TAK-981 + Avelu... | 18 Years - | Presage Biosciences | |
| Naltrexone and Propranolol Combined With Immunotherapy | NCT05968690 | Advanced Melano... | Propranolol Naltrexone | 18 Years - | Rutgers, The State University of New Jersey |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
